Close Menu

NEW YORK – Predictive Technology Group and Atrin Pharmaceuticals have partnered to develop molecular diagnostics to expedite improved selection of cancer patients who will benefit from treatment with DNA damage and response (DDR) inhibitors.

The partners plan to develop actionable predictive molecular and companion diagnostics and therapeutics for common disorders and related cancers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.